Business
Aptevo is a clinical-stage biotechnology company developing immunotherapy candidates for cancer using ADAPTIR and ADAPTIR-FLEX platforms.
Aptevo had no revenue in FY2025, the net loss widened to $26.0M, and cash from ops weakened.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage immunotherapyNote
- Revenue — No revenue in the bundleNote
- Profitability — Net loss widened to $26.0MWatch
- Cash — Cash from ops was negative $25.6MWatch
- Balance sheet — Equity rose to $17.4MOK
- Insiders — 1 buy / 0 sellsOK
- Accounting — Latest forensic year showed Altman-Z distressWatch
Leadership changes
From Aptevo Therapeutics Inc.'s own filings, the day they're filed.
- Jeff Lamothe · Chief Operating Officer · appointment
Latest filings
- 8-K · Company announcement2026-09-03
- DEF 14A · Annual proxy (pay & governance)2026-08-31
- 8-K · Company announcement2026-08-21
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-08-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Aptevo Therapeutics Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.